(NASDAQ GS: AMRS)
Attention investors who purchased shares of Amyris, Inc. before March 15, 2018:
Rigrodsky & Long is investigating claims brought in a securities fraud class action complaint against Amyris, Inc. ("Amyris") concerning whether Amyris and certain of the Company's directors and/or officers made materially false and misleading statements and failed to disclose materially adverse facts during the period March 15, 2018 and March 19, 2019, inclusive (the "Class Period"), concerning Amyris's business, operations and prospects. These misrepresentations and omissions artificially inflated the price of Amyris's stock throughout the Class Period.
Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities that purchased the common stock of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ GS: AMRS) between March 15, 2018 and March 19, 2019, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of Amyris during the Class Period, or purchased shares prior to the Class Period and still hold Amyris, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Seth D. Rigrodsky or Timothy J. MacFall at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at http://rigrodskylong.com/contact-us/.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public: (1) that the Company lacked sufficient resources to accurately account for certain transactions; (2) that, as a result, there was a material weakness in the Company’s internal controls over financial reporting; (3) that, as a result, the Company would be unable to timely file its annual report; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on March 19, 2019, the Company disclosed that it would be unable to timely file its annual report due to “significant time and resources that were devoted to the accounting for and disclosure of the significant transactions with Koninklijke DSM N.V. that closed in November 2018.” The Company also disclosed that it “is in the process of completing its evaluation of internal control over financial reporting and may have further deficiencies to report.”
On this news, shares of Amyris declined over 20%, closing at $3.10 per share on March 20, 2019, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.